Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0451
Source ID: NCT01857024
Associated Drug: Sevelamer Carbonate (Renvela®)
Title: Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Hyperphosphataemia|Chronic Kidney Disease
Interventions: DRUG: sevelamer carbonate (Renvela®)
Outcome Measures: Primary: Frequency of non-serious and Serious Adverse Drug Reaction (ADRs), Assess safety profile of Renvela tablets and powder, 12 Months |
Sponsor/Collaborators: Sponsor: Genzyme, a Sanofi Company
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 210
Study Type: OBSERVATIONAL
Study Designs: Observational Model: |Time Perspective: p
Start Date: 2010-09
Completion Date: 2012-10
Results First Posted:
Last Update Posted: 2015-03-23
Locations: Graz, Austria|Linz, Austria|Aalborg, Denmark|Cabestany, France|Dijon, France|Lille, France|St. Laurent du Var, France|Toulouse, France|Berlin, Germany|Dortmund, Germany|Hannover, Germany|Mettman, Germany|Wiesbaden, Germany|Acireale, Italy|Milano, Italy|Naples, Italy|Palermo, Italy|Pavia, Italy|Pesaro, Italy|Rome, Italy|Amsterdam, Netherlands|Breda, Netherlands|Dordrecht, Netherlands|Leiden, Netherlands|Madrid, Spain|Valencia, Spain
URL: https://clinicaltrials.gov/show/NCT01857024